ArticleFrontiers in cardiovascular medicine2026
Risk assessment of acute heart failure after endovascular therapy in acute ischemic stroke: a nomogram-based study.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute heart failure (AHF) is a life-threatening complication following endovascular therapy (EVT) for acute ischemic stroke with large vessel occlusion (AIS-LVO). This study aims to identify independent predictors of AHF after EVT and to develop and validate a nomogram for individualized risk prediction. Methods: We retrospectively enrolled data from patients with acute ischemic stroke with large vessel occlusion who underwent endovascular treatment between September 2021 and June 2025 were analysed in October 2025. After screening based on inclusion and exclusion criteria, 457 patients were randomly allocated into training ( Results: Multivariate analysis identified five independent predictors of AHF after EVT: atrial fibrillation, valvular heart disease, left ventricular ejection fraction, serum creatinine, and troponin T. The nomogram demonstrated excellent discriminative ability, with an AUC of 0.909 (95% CI: 0.837-0.980) in the validation cohort. Calibration curves indicated good agreement between predicted and observed risks. DCA and CIC confirmed the model's favorable clinical net benefit. Conclusion: We developed and validated a five-factor nomogram that effectively predicts the individualized risk of AHF following EVT in patients with AIS-LVO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.